APA (7th ed.) Citation

Yap, T., Lemech, C., Voskoboynik, M., Millward, M., Hafez, M., Tam, L., . . . Lorusso, P. (2025). 923MO First results from a phase I trial of SNV1521, a next generation, CNS-penetrant, PARP1-selective inhibitor in patients (pts) with molecularly selected advanced solid tumors. Annals of Oncology, 36, S603. https://doi.org/10.1016/j.annonc.2025.08.1492

Chicago Style (17th ed.) Citation

Yap, T.A, et al. "923MO First Results from a Phase I Trial of SNV1521, a Next Generation, CNS-penetrant, PARP1-selective Inhibitor in Patients (pts) with Molecularly Selected Advanced Solid Tumors." Annals of Oncology 36 (2025): S603. https://doi.org/10.1016/j.annonc.2025.08.1492.

MLA (9th ed.) Citation

Yap, T.A, et al. "923MO First Results from a Phase I Trial of SNV1521, a Next Generation, CNS-penetrant, PARP1-selective Inhibitor in Patients (pts) with Molecularly Selected Advanced Solid Tumors." Annals of Oncology, vol. 36, 2025, p. S603, https://doi.org/10.1016/j.annonc.2025.08.1492.